Pleconaril: A broad spectrum antipicornaviral agent

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 69-76

  Rogers, J M ^a   Diana, G D ^a   McKinlay, M A ^a  

^a Viropharma Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIVIRUS AGENT; INTERCELLULAR ADHESION MOLECULE 1; PLECONARIL;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMMON COLD; CONFERENCE PAPER; COST OF ILLNESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HUMAN; INFLUENZA; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

PICORNAVIRIDAE;

EID: 0033281792     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_7     Document Type: Conference Paper

References (29)

1. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment
2. The site of attachment of human rhinovirus 14 and antiviral agents that inhibit uncoating
3. Antipicornavirus drugs: Current status
4. Development of antiviral agents for picornavirus infections
5. Safety and efficacy of oral pirodavir (R 77975) in experimental rhinovirus infection
6. Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness
7. Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirus infection
8. Picornavirus inhibitors: Triflouromethyl substitution provides a global protective effect against hepatic metabolism
9. Enterovirus meningitis in adults
10. Enteroviral infections of the central nervous system
11. Acute meningitis with a negative Gram's stain: Clinical and management outcomes in 171 episodes
12. Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis
13. In vitro activity of VP 63843 against field isolates of non-polio enteroviruses
14. Pharmacokinetics of pleconaril in adults
15. Pharmacokinetics of pleconaril in children
16. Oral efficacy of VP 63843 in coxsackievirus A21 infected volunteers
17. Factors influencing response of volunteers to inoculation with coxsackievirus A type 21
18. Production of illness with a small-particle aerosol of coxsackie A21
19. Treatment of enterovirus meningitis with pleconaril (VP 63843) an antipiconaviral agent
20. Chronic enteroviral meningoencephalitis in agammagolbulinemic patients
21. Diagnosis of enterovirus brain disease in hypogammaglobulinemic patients by polymerase chain reaction
22. Pleconaril treatment of chronic enteroviral central nervous system infections in children with agammaglobulinemia
23. The contribution of respiratory viruses to severe exacerbations of asthma in adults
24. Association of rhinovirus infection with poor bacteriologic outcome of bacterial viral otitis media
25. Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction